GSK shares rise after £1.7bn Zantac settlement October 10, 2024 GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Meet the founder searching for the ‘holy grail’ of cancer treatment October 8, 2024 Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry
Astrazeneca boosts cardiovascular pipeline with licensing deal October 7, 2024 Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Vet service Animalcare reports positive results after balance sheet “transformation” September 24, 2024 International veterinary pharmaceutical and services business Animalcare has reported a “transformation” in its balance sheet after two sales worth £27.7m, as well as a boost in revenue. The AIM-listed, York-based company told markets this morning that its revenue rose by five per cent to £36.9m, from £35.2m in the first half of 2023. Underlying earnings [...]
AMS Group reports ‘strong’ first half amid rumoured takeover interest September 18, 2024 In the six months to June, revenue rose by eight per cent to £68.0m, with strong growth in the firm's surgical business unit offsetting "challenges" in its Woundcare unit.
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
Fusion Antibodies: Pharma firm has ‘challenging’ year despite strong sales pipeline September 5, 2024 Pharmaceutical company Fusion Antibodies said it had a “challenging” year but has seen its sales pipeline grow. Fusion posted audited revenue of £1.14m for the year ended March 2024, a 60 per cent drop from the £2.9m it reported in 2023. The company, which specialises in antibody discovery, engineering and supply for therapeutic drugs, said [...]
Private equity groups circle UK pharmacy wholesaler September 2, 2024 HIG and Capvest have joined a line of private equity groups looking to buy the largest supplier of goods to British pharmacies, AAH Pharmaceuticals, from German private equity firm Aurelius. AAH has been put up for sale again only a few years after being bought by Aurelius in 2022, according to the Financial Times. The [...]
Curing cancer and cleaning our oceans? Here’s why I’m betting on biotech September 1, 2024 Something that can cure cancer and clean our oceans? Biotech sounds too good to be true, but some things really are just like magic, writes Andrew Craig.
AS Watson: Pharma partner Icanthera’s cash reserves soar August 27, 2024 UK-based pharmaceutical company Icanthera said its cash reserves soared over the last year as it has struck a major deal and is focusing on developing new products. The company that manufactures dermatology and oncology treatments said its cash position increased to £61,000 at 31 March 2024, up from £3,000 in the previous year. Icanthera said [...]